目的 通過(guò)對(duì)苯達(dá)莫司汀發(fā)表的有關(guān)藥品不良反應(yīng)（ADR）的病例報(bào)道進(jìn)行分析，以期為臨床安全合理應(yīng)用提供參考依據(jù)。方法 通過(guò)檢索Web of Science、PubMed、Wiley Online Library、中國(guó)知網(wǎng)、萬(wàn)方和維普數(shù)據(jù)庫(kù)中有關(guān)苯達(dá)莫司汀上市后ADR的病例報(bào)道，采用回顧性分析方法，對(duì)患者的基本情況、ADR發(fā)生時(shí)間、臨床表現(xiàn)、累及器官/系統(tǒng)、處理及轉(zhuǎn)歸等信息進(jìn)行整理分析。結(jié)果 共收集27例病例，其中男性16例，女性11例；年齡28～75歲，平均年齡（62.11±9.47）歲。ADR多發(fā)生在用藥3個(gè)周期內(nèi)，累及7個(gè)系統(tǒng)/器官，其中以皮膚及皮下組織與血液系統(tǒng)最為常見(jiàn)（37.04%、33.33%）。結(jié)論 苯達(dá)莫司汀皮膚及血液系統(tǒng)ADR發(fā)生率較高，用藥過(guò)程應(yīng)密切監(jiān)測(cè)。此外要特別關(guān)注苯達(dá)莫司汀長(zhǎng)期給藥及罕見(jiàn)ADR的監(jiān)護(hù)。

Objective To analyze the adverse drug reactions (ADR) case reports published by bendamustine in order to provide a reference for safety and reasonable use of bendamustine in clinical practice. Methods The cases reports of bendamustine were searched in Web of Science, Pubmed, Wiley Online Library, CNKI, Wanfang, and VIP. The basic patient information, adverse reaction time, clinical characters, involved systems organs, treatment and outcomes were collected and analyzed. Results A total of 27 cases were collected, including 16 males and 11 females. The age ranged from 28 to 75 years, and the overall mean age was (62.11 ±9.47) years. ADR mostly occurred within 3 cycles of medication and involved 7 systems/organs, among which skin, subcutaneous tissue and blood system were the most common (37.04%, 33.33%). Conclusion Bendamustine has a high incidence of ADR in skin and blood system, and the course of medication should be closely monitored. In addition, special attention should be paid to long-term administration of bendamustine and monitoring of rare ADR.

R979.1